PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

Key Points Genetic analysis reveals frequent 9p24.1/PD-L1/PD-L2 copy-number alterations and increased expression of the PD-1 ligands in PCNSL and PTL. PD-1 blockade with nivolumab demonstrated activity in patients with relapsed/refractory PCNSL and PTL.